Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.88 |
| ▸ | HTR7 | P34969 | 3/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029527 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| Isoboldine SCHEMBL29486797 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| Isoboldine SCHEMBL29700583 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| Isoboldine SCHEMBL12140647 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| SCHEMBL30096101 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| Isoboldine SCHEMBL11240744 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| SCHEMBL14029497 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| SCHEMBL11254471 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| SCHEMBL14124100 | 0.93 | ALDH1A1 (0.86) | ALDH1A1KDM4EHSD17B10HPGDMAPT | |
| SCHEMBL11246440 | 0.93 | ALDH1A1 (0.86) | ALDH1A1KDM4EHSD17B10HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067187-B2 | Cross-β structure binding compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2011-11-29 | — | — | US | claimed |
| CN-119943132-A | Dactylicapnos pain-relieving related quality marker, screening method and application thereof | 中国科学院大连化学物理研究所 | 2025-05-06 | — | — | CN | disclosed |
| CN-105833131-A | Preparation for treating gastric ulcer and duodenal ulcer and preparation method | 张桂臣 | 2016-08-10 | — | — | CN | disclosed |
| CN-105770760-A | Preparation for treating gastric ulcer and preparation method thereof | 张桂臣 | 2016-07-20 | — | — | CN | disclosed |
| US-8460642-B2 | Boldline compounds for promoting bone growth | OssiFi, Inc. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120301509-A1 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH | OSTEOGENEX, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8202995-B2 | Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2012-06-19 | — | — | US | disclosed |
| US-8202995-B2 | Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2012-06-19 | — | — | US | disclosed |
| US-8202995-B2 | Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2012-06-19 | — | — | US | disclosed |
| EP-1910844-B1 | CROSS-BETA STRUCTURE BINDING COMPOUNDS | CROSSBETA BIOSCIENCES BV (NL) | 2012-04-18 | — | — | EP | disclosed |
| WO-2002016325-A1 | USES OF THALIPORPHINE OR ITS DERIVATIVES IN TREATMENT OF CARDIAC DISEASES AND PREPARATION OF SAME | SU MINGJAI (CN) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016325-A1 | USES OF THALIPORPHINE OR ITS DERIVATIVES IN TREATMENT OF CARDIAC DISEASES AND PREPARATION OF SAME | SU MINGJAI (CN) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016325-A1 | USES OF THALIPORPHINE OR ITS DERIVATIVES IN TREATMENT OF CARDIAC DISEASES AND PREPARATION OF SAME | SU MINGJAI (CN) | 2002-02-28 | — | — | WO | disclosed |
| US-6313134-B1 | FOR THERAPY AND PROPHYLAXIS OF CARDIAC DISEASE SELECTED FROM THE GROUP CONSISTING OF CARDIAC ARRHYTHMIA, MYOCARDIAL ISCHEMIA, MYOCARDIAL INFARCTION, SUDDEN DEATH CAUSED BY CARDIAC ARRHYTHMIAMYOCARDIAL INFARCTION | NATIONAL SCIENCE COUNCIL (TW) | 2001-11-06 | — | — | US | disclosed |
| US-6313134-B1 | FOR THERAPY AND PROPHYLAXIS OF CARDIAC DISEASE SELECTED FROM THE GROUP CONSISTING OF CARDIAC ARRHYTHMIA, MYOCARDIAL ISCHEMIA, MYOCARDIAL INFARCTION, SUDDEN DEATH CAUSED BY CARDIAC ARRHYTHMIAMYOCARDIAL INFARCTION | NATIONAL SCIENCE COUNCIL (TW) | 2001-11-06 | — | — | US | disclosed |
| US-6313134-B1 | FOR THERAPY AND PROPHYLAXIS OF CARDIAC DISEASE SELECTED FROM THE GROUP CONSISTING OF CARDIAC ARRHYTHMIA, MYOCARDIAL ISCHEMIA, MYOCARDIAL INFARCTION, SUDDEN DEATH CAUSED BY CARDIAC ARRHYTHMIAMYOCARDIAL INFARCTION | NATIONAL SCIENCE COUNCIL (TW) | 2001-11-06 | — | — | US | disclosed |
| WO-1999016441-A1 | APORPHINOID MATRIX METALLOPROTEINASE INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-04-08 | — | — | WO | disclosed |
| US-4309542-A | WITH A TRIMETHYLPHENYLAMMONIUM BASE | WARNER-LAMBERT COMPANY (US) | 1982-01-05 | — | — | US | disclosed |
| US-4202980-A | Process for the preparation of 1-hydroxyaporphine-derivatives | WARNER-LAMBERT COMPANY (US) | 1980-05-13 | — | — | US | disclosed |
| US-4120964-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301509-A1 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH | BMP2, BMP1, FGF23 | ALDH1A1 3250/4885KDM4E 597/4885HSD17B10 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.